Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
CARMA FUND Management GmbH operates CARMA FUND I, an early-stage investment fund established in June 2022. The fund is headquartered in Munich and Frankfurt am Main, Germany, and manages approximately €56 million. CARMA FUND I focuses on translating academic and institutional life-science research into commercial ventures, supporting innovators in developing new products and services that enhance patient well-being and drive medical advancements.
The fund's investment strategy encompasses pre-seed to Series A stages, primarily targeting startups within the life sciences and healthcare sectors across Europe. CARMA FUND I has established partnerships with key institutions, including Ascenion GmbH, Goethe-University Frankfurt am Main, and the European Investment Fund (EIF), which serve as significant sources of deal flow and collaboration.
Since its inception, CARMA FUND I has actively sought to advance healthcare innovations, demonstrating a commitment to supporting early-stage companies that are developing groundbreaking therapeutic and diagnostic solutions. The fund's notable milestones include the first closing of €47 million in June 2022, with Evotec SE and EIF as anchor investors.
CARMA FUND I invests in early-stage companies and projects within the life sciences and medical sectors, with a particular emphasis on healthcare innovations. The fund welcomes applications for funding from all European sources, aiming to support startups that are developing innovative therapeutic and diagnostic solutions, as well as digital health technologies. The investment strategy covers a wide range of areas, including new therapeutic approaches, platform technologies, medical devices, and digital health.
Investment stages range from pre-seed to Series A, allowing CARMA FUND I to engage with startups at various points in their development. The fund seeks to partner with founders who demonstrate a strong commitment to advancing medical technologies and improving patient outcomes. CARMA FUND I values innovative ideas that can translate academic research into viable commercial products, thereby enhancing the quality of healthcare delivery.
CARMA FUND I has built a diverse portfolio of 16 companies, each contributing to advancements in life sciences and healthcare. Notable portfolio companies include:
This portfolio reflects CARMA FUND I's commitment to supporting innovative solutions that address critical challenges in healthcare and life sciences.
To pitch CARMA FUND I, founders should reach out via email at info@carma-fund.com. It is advisable to include a concise overview of the startup, the problem it addresses, and the proposed solution in the initial communication. A well-structured pitch deck that outlines the business model, market opportunity, and team background is essential.
While specific response time expectations are not provided, founders should anticipate a thorough review process. Warm introductions through mutual connections in the life sciences or healthcare sectors may enhance the chances of receiving a timely response.
As of April 2023, CARMA FUND I has been actively expanding its portfolio, currently comprising 16 companies. The fund's focus on early-stage investments in life sciences has led to notable partnerships with academic institutions and strategic investors.
In June 2022, CARMA FUND I announced its first closing of €47 million, with Evotec SE and the European Investment Fund (EIF) as key anchor investors. This milestone marked a significant step in the fund's mission to support healthcare innovations.
What are CARMA FUND's investment criteria?
CARMA FUND I invests in early-stage companies and projects within the life sciences and medical sectors, particularly those developing innovative therapeutic and diagnostic solutions, as well as digital health technologies.
How can I apply or pitch to CARMA FUND?
Founders can submit their applications for funding via email at info@carma-fund.com. The fund welcomes applications from all European sources.
What makes CARMA FUND different from other investors?
CARMA FUND I leverages a strong network of academic and institutional partners, providing access to cutting-edge research and development resources, which enhances the support offered to portfolio companies.
What is the geographic scope of CARMA FUND's investments?
The fund focuses on early-stage investments across Europe, welcoming applications from startups based in various European countries.
What is the typical check size for investments?
While specific check sizes are not disclosed, CARMA FUND I invests in early-stage companies, typically at the pre-seed to Series A stages.
What kind of post-investment involvement does CARMA FUND have?
CARMA FUND I provides strategic guidance and support to its portfolio companies, helping them navigate the complexities of the life sciences sector and accelerate their growth.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.